Finance

Lists
BRNS:NASDAQ
Barinthus Biotherapeutics PLC - ADR
$0.62
+4.47%
(+0.026) 1D
Aug 18, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BRNS...
Open
$0.62
High
$0.66
Low
$0.62
Mkt. cap
25.48M
Avg. vol.
39.30K
Volume
74.58K
52-wk high
$1.83
52-wk low
$0.51
EPS
-$1.02
Beta
-0.39
Shares outstanding
40.85M
No. of employees
14
Open
$0.62
High
$0.66
Low
$0.62
Mkt. cap
25.48M
Avg. vol.
39.30K
Volume
74.58K
52-wk high
$1.83
52-wk low
$0.51
EPS
-$1.02
Beta
-0.39
Shares outstanding
40.85M
No. of employees
14
Profile
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people. Wikipedia
About Barinthus Biotherapeutics PLC - ADR
CEO-
Employees14
Founded2016
Headquarters-
SectorBiotechnology
Analyst ratings
Based on 1 analyst giving stock ratings to BRNS in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for BRNS in the last 3 months
Highest
Current $0.62
$6.00 (+867.74%)
Average
$6.00 (+867.74%)
Lowest
$6.00 (+867.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Maintained
$6.00
+867.7%
08/06/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$4.00
+545.2%
12/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-308.00K
374.00K
271.00K
3.92M
Cost of revenue
-308.00K
374.00K
271.00K
3.92M
Research and development expenses
5.46M
3.44M
3.17M
-42.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.15M
1.50M
2.38M
7.03M
Operating expense
10.53M
4.51M
5.50M
6.98M
Total operating expenses
10.23M
4.88M
5.78M
10.91M
Operating income
-10.23M
-4.88M
-5.78M
-10.91M
Other non operating income
-275.00K
-104.00K
39.00K
26.00K
EBT including unusual items
-14.64M
-11.16M
-5.55M
-10.62M
EBT excluding unusual items
-10.04M
-4.59M
-5.40M
-10.55M
Income tax expense
-71.00K
-57.00K
-16.00K
-23.00K
Effective tax rate
0.48%
0.51%
0.29%
0.22%
Other operating expenses
-72.00K
-434.00K
-46.00K
-5.00K
Net income
-14.57M
-11.09M
-5.53M
-10.58M
Net profit margin
-
-
-
-
Earnings per share
-0.24
-0.27
-0.14
-0.26
Interest and investment income
472.00K
406.00K
350.00K
343.00K
Interest expense
-13.00K
-13.00K
-13.00K
-14.00K
Net interest expenses
459.00K
393.00K
337.00K
329.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.12M
-4.57M
-5.52M
-10.69M
Gain or loss from assets sale
-68.00K
104.00K
-38.00K
-32.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps